Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia

63Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

Abstract

Purpose: In acute myeloid leukemia (AML), studies based on whole-genome sequencing have shown genomic diversity within leukemic clones. The aim of this study was to address clonal heterogeneity in AML based on metaphase cytogenetics. Patients and Methods: This analysis included all patients enrolled onto two consecutive, prospective, randomized multicenter trials of the Study Alliance Leukemia. Patients were newly diagnosed with non-M3 AML and were fit for intensive chemotherapy. Results: Cytogenetic subclones were detected in 418 (15.8%) of 2,639 patients from the whole study population and in 418 (32.8%) of 1,274 patients with aberrant karyotypes. Among those, 252 karyotypes (60.3%) displayed a defined number of distinct subclones, and 166 (39.7%) were classified as composite karyotypes. Subclone formation was particularly frequent in the cytogenetically adverse group, with subclone formation in 69.0%, 67.1%, and 64.8% of patients with complex aberrant, monosomal, and abnl(17p) karyotypes (P < .001 each). Two-subclone patterns typically followed a mother-daughter evolution, whereas for ≥ three subclones, a branched pattern prevailed. In non-core binding factor AML, subclone formation was associated with inferior event-free and overall survival and was confirmed as an independent predictor of poor prognosis in multivariate analysis. Subgroup analysis showed that subclone formation adds prognostic information particularly in the cytogenetic adverse-risk group. Allogeneic stem-cell transplantation improved the prognosis of patients with subclone karyotypes as shown in landmark analyses. Conclusion: Cytogenetic subclones are frequent in AML and permit tracing of clonal evolution and architecture. They bear prognostic significance with clonal heterogeneity as an independent adverse prognostic marker in cytogenetically adverse-risk AML. © 2013 by American Society of Clinical Oncology.

References Powered by Scopus

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

6414Citations
N/AReaders
Get full text

Genetic Alterations during Colorectal-Tumor Development

6239Citations
N/AReaders
Get full text

Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet

2846Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pan-cancer analysis of the extent and consequences of intratumor heterogeneity

569Citations
N/AReaders
Get full text

Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study

362Citations
N/AReaders
Get full text

Intratumoral Heterogeneity of the Epigenome

163Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bochtler, T., Stol̈zel, F., Heilig, C. E., Kunz, C., Mohr, B., Jauch, A., … Kram̈er, A. (2013). Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. Journal of Clinical Oncology, 31(31), 3898–3905. https://doi.org/10.1200/JCO.2013.50.7921

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 28

53%

Researcher 12

23%

Professor / Associate Prof. 8

15%

Lecturer / Post doc 5

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 24

45%

Agricultural and Biological Sciences 16

30%

Biochemistry, Genetics and Molecular Bi... 11

21%

Pharmacology, Toxicology and Pharmaceut... 2

4%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free